Posted by Michael Wonder on 02 Dec 2025
GSK’s Jemperli now standard in endometrial cancer as reimbursement expands to first-line therapy
1 December 2025 - GSK’s Jemperli has secured its position as a standard treatment option in endometrial cancer following Korea’s decision to grant reimbursement for first-line use in patients with mismatch repair deficient or microsatellite instability high disease.
Jemperli, a PD-1 inhibitor, received its first approval in Korea in December 2022 for patients with deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) endometrial cancer whose disease had progressed after prior platinum-based chemotherapy.
The drug was reimbursed for this use in 2023, marking its Korean market launch.
In March 2024, the indication broadened to include first-line combination therapy with carboplatin and paclitaxel in newly diagnosed advanced or recurrent dMMR or MSI-H disease.
In December 2024, the regulatory scope was further expanded to allow first-line use regardless of MMR status. Reimbursement for the dMMR and MSI-H first-line combination was approved on 1 October this year, making Jemperli the only reimbursed option in both first- and second-line settings in Korea as of December 2025.
